These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 3738427

  • 21. Editorial: Thalassemia major: a problem of iron overload.
    Stockman JA, Oski FA.
    Ann Intern Med; 1974 Aug; 81(2):262-3. PubMed ID: 4846109
    [No Abstract] [Full Text] [Related]

  • 22. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH, Wu KH, Tsai FJ, Peng CT, Tsai CH.
    Hemoglobin; 2006 Aug; 30(2):257-62. PubMed ID: 16798651
    [Abstract] [Full Text] [Related]

  • 23. Current status of iron chelation therapy with deferoxamine.
    Cohen A.
    Semin Hematol; 1990 Apr; 27(2):86-90. PubMed ID: 2190321
    [Abstract] [Full Text] [Related]

  • 24. Combined long-term treatment of hemosiderosis with desferioxamine and DTPA in homozygous beta-thalassemia.
    Constantoulakis M, Economidou J, Karagiorga M, Katsantoni A, Gyftaki E.
    Ann N Y Acad Sci; 1974 Apr; 232(0):193-200. PubMed ID: 4528481
    [No Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 Apr; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 26. Treatment of iron overload in adults with continuous parenteral desferrioxamine.
    Cooper B, Bunn HF, Propper RD, Nathan DG, Rosenthal DS, Moloney WC.
    Am J Med; 1977 Dec; 63(6):958-66. PubMed ID: 605917
    [Abstract] [Full Text] [Related]

  • 27. Subcutaneous diethylene triamine pentaacetic acid: comparison with desferrioxamine in thalassemic patients with iron overload.
    Pippard MJ, Jackson MJ, Modell CB.
    Birth Defects Orig Artic Ser; 1988 Dec; 23(5B):105-9. PubMed ID: 3390531
    [No Abstract] [Full Text] [Related]

  • 28. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [Abstract] [Full Text] [Related]

  • 29. Liposome entrapped desferrioxamine and iron transporting ionophores: a new approach to iron chelation therapy.
    Young SP, Baker E, Huehns ER.
    Br J Haematol; 1979 Mar; 41(3):357-63. PubMed ID: 427040
    [Abstract] [Full Text] [Related]

  • 30. A study of the mechanisms and sites of action of desferrioxamine in thalassaemia major.
    Bianco I, Graziani B, Lerone M, Congedo P, Clemente GF, Ingrao G, Ciccone F, Di Nucci GD, Mandelli F, Isacchi G.
    Acta Haematol; 1984 Mar; 71(2):100-5. PubMed ID: 6421046
    [Abstract] [Full Text] [Related]

  • 31. Iron chelation therapy for patients with sickle cell disease and iron overload.
    Inati A, Khoriaty E, Musallam KM, Taher AT.
    Am J Hematol; 2010 Oct; 85(10):782-6. PubMed ID: 20721892
    [No Abstract] [Full Text] [Related]

  • 32. Prevention of iron loading in transfusion-dependent thalassaemia.
    Pippard MJ, Letsky EA, Callender ST, Weatherall DJ.
    Lancet; 1978 Jun 03; 1(8075):1178-81. PubMed ID: 77945
    [Abstract] [Full Text] [Related]

  • 33. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA, Foster RH.
    Drugs; 1999 Sep 03; 58(3):553-78. PubMed ID: 10493280
    [Abstract] [Full Text] [Related]

  • 34. Deferoxamine and diethylenetriaminepentaacetic acid (DTPA) in thalassemia.
    McDonald R.
    J Pediatr; 1966 Oct 03; 69(4):563-71. PubMed ID: 5921331
    [No Abstract] [Full Text] [Related]

  • 35. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ.
    Cochrane Database Syst Rev; 2007 Jul 18; (3):CD004839. PubMed ID: 17636775
    [Abstract] [Full Text] [Related]

  • 36. Reassessment of the use of desferrioxamine B in iron overload.
    Propper RD, Shurin SB, Nathan DG.
    N Engl J Med; 1976 Jun 24; 294(26):1421-3. PubMed ID: 1272274
    [Abstract] [Full Text] [Related]

  • 37. High-dose intravenous chelation therapy with deferoxamine.
    Cohen A, Mizanin J, Schwartz E.
    Prog Clin Biol Res; 1989 Jun 24; 309():125-31. PubMed ID: 2780746
    [No Abstract] [Full Text] [Related]

  • 38. Combined oral and parenteral iron chelation in beta thalassaemia major.
    Balveer K, Pyar K, Wonke B.
    Med J Malaysia; 2000 Dec 24; 55(4):493-7. PubMed ID: 11221163
    [Abstract] [Full Text] [Related]

  • 39. Recent developments in iron chelation therapy.
    Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E.
    Klin Padiatr; 2007 Dec 24; 219(3):158-65. PubMed ID: 17525910
    [Abstract] [Full Text] [Related]

  • 40. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients.
    Olivieri NF, Koren G, Hermann C, Bentur Y, Chung D, Klein J, St Louis P, Freedman MH, McClelland RA, Templeton DM.
    Lancet; 1990 Nov 24; 336(8726):1275-9. PubMed ID: 1978115
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.